Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage specialty pharmaceutical company focusing on rare and orphan diseases, has announced plans to release its second quarter 2024 financial results before market opening on Thursday, August 8, 2024. The upcoming announcement will include an operational update highlighting the company's achievements during the quarter, along with financial highlights. This pre-market release will provide investors and analysts with important information about Quoin's performance and progress in its specialized field of rare disease therapeutics.
Quoin Pharmaceuticals (NASDAQ: QNRX), un'azienda farmaceutica specializzata in fase clinica che si concentra su malattie rare e orfane, ha annunciato piani per pubblicare i suoi risultati finanziari del secondo trimestre 2024 prima dell'apertura del mercato giovedì 8 agosto 2024. L'annuncio imminente includerà un aggiornamento operativo che evidenzia i risultati dell'azienda durante il trimestre, insieme a elementi salienti finanziari. Questo rilascio pre-mercato fornirà agli investitori e agli analisti informazioni importanti sulle prestazioni e i progressi di Quoin nel suo campo specializzato delle terapie per le malattie rare.
Quoin Pharmaceuticals (NASDAQ: QNRX), una empresa farmacéutica especializada en etapa clínica enfocada en enfermedades raras y huérfanas, ha anunciado planes para publicar sus resultados financieros del segundo trimestre de 2024 antes de la apertura del mercado el jueves 8 de agosto de 2024. El próximo anuncio incluirá una actualización operativa que destacará los logros de la empresa durante el trimestre, junto con aspectos financieros destacados. Este comunicado anterior a la apertura brindará a los inversores y analistas información importante sobre el rendimiento y el progreso de Quoin en su campo especializado de terapias para enfermedades raras.
Quoin Pharmaceuticals (NASDAQ: QNRX)는 희귀 및 외래 질환에 중점을 둔 임상 단계 전문 제약 회사로, 2024년 2분기 재무 결과를 2024년 8월 8일 목요일에 시장 개장 전에 발표할 계획을 발표했습니다. 다가오는 발표에는 분기 동안 회사의 성과를 강조하는 운영 업데이트와 재무 하이라이트가 포함될 것입니다. 이번 시장 개장 전 발표는 Quoin의 성과와 희귀 질환 치료의 전문 분야에서의 진전을 투자자 및 애널리스트들에게 중요한 정보를 제공할 것입니다.
Quoin Pharmaceuticals (NASDAQ: QNRX), une entreprise pharmaceutique spécialisée en phase clinique axée sur les maladies rares et orphelines, a annoncé ses intentions de publier ses résultats financiers du deuxième trimestre 2024 avant l'ouverture des marchés le jeudi 8 août 2024. L'annonce à venir comprendra une actualisation opérationnelle soulignant les réalisations de l'entreprise au cours du trimestre, ainsi que des éléments financiers marquants. Cette publication avant l'ouverture du marché fournira aux investisseurs et aux analystes des informations importantes sur les performances et les progrès de Quoin dans son domaine spécialisé des thérapies pour les maladies rares.
Quoin Pharmaceuticals (NASDAQ: QNRX), ein auf klinischer Stufe befindliches spezialisiertes Pharmaunternehmen, das sich auf seltene und verwaiste Krankheiten konzentriert, hat Pläne angekündigt, seine Finanzergebnisse für das zweite Quartal 2024 vor der Eröffnung des Marktes am Donnerstag, den 8. August 2024 bekannt zu geben. Die bevorstehende Ankündigung wird ein Betriebsupdate enthalten, das die Erfolge des Unternehmens im Quartal hervorhebt, zusammen mit finanziellen Höhepunkten. Diese Vorabveröffentlichung wird Investoren und Analysten wichtige Informationen über Quoins Leistung und Fortschritte in seinem spezialisierten Bereich der Therapie seltener Krankheiten bieten.
- None.
- None.
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024.
The announcement will provide an operational update regarding the company’s achievements during the quarter and will detail financial highlights.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. For additional information concerning factors that could cause actual results to differ materially from the information contained in this press release, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 that the Company filed with the SEC and the Company’s subsequent filings with the SEC on Forms 10-Q and 8-K. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals (QNRX) release its Q2 2024 financial results?
What information will be included in Quoin Pharmaceuticals' (QNRX) Q2 2024 financial report?
What is the primary focus of Quoin Pharmaceuticals (QNRX)?
On which stock exchange is Quoin Pharmaceuticals (QNRX) listed?
